Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis

Geijer, Håkan; Breimer, Lars H.

doi:10.1007/s00259-013-2482-z

Cited by 182 publications

(106 citation statements)

References 53 publications

Supporting

Mentioning

101

Contrasting

Unclassified

Order By: Relevance

“…It may be argued that 68 Ga-based tracers such as 68 Ga-DOTATATE, 68 Ga-DOTATOC, or 68 Ga-DOTANOC would equally perform better than 111 In-DTPA-OC (30). Indeed, such comparative studies also found more foci identified with 68 Ga-based tracers than with SPECT (27,31,32).…”

Section: Discussionmentioning

confidence: 84%

⁶⁴Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with ¹¹¹In-DTPA-Octreotide in 112 Patients

et al. 2015

View full text Add to dashboard Cite

Neuroendocrine tumors (NETs) can be visualized using radiolabeled somatostatin analogs. We have previously shown the clinical potential of 64 Cu-DOTATATE in a small first-in-human feasibility study. The aim of the present study was, in a larger prospective design, to compare on a head-to-head basis the performance of 64 In-diethylenetriaminepentaacetic acid (DTPA)-octreotide ( 111 In-DTPA-OC) as a basis for implementing 64 Cu-DOTATATE as a routine. Methods: We prospectively enrolled 112 patients with pathologically confirmed NETs of gastroenteropancreatic or pulmonary origin. All patients underwent both PET/CT with 64 Cu-DOTATATE and SPECT/CT with 111 In-DTPA-OC within 60 d. PET scans were acquired 1 h after injection of 202 MBq (range, 183-232 MBq) of 64 Cu-DOTATATE after a diagnostic contrast-enhanced CT scan. Patients were followed for 42-60 mo for evaluation of discrepant imaging findings. The McNemar test was used to compare the diagnostic performance. Results: Eightyseven patients were congruently PET-and SPECT-positive. No SPECT-positive cases were PET-negative, whereas 10 false-negative SPECT cases were identified using PET. The diagnostic sensitivity and accuracy of 64 Cu-DOTATATE (97% for both) were significantly better than those of 111 In-DTPA-OC (87% and 88%, respectively, P 5 0.017). In 84 patients (75%), 64 Cu-DOTATATE identified more lesions than 111 In-DTPA-OC and always at least as many. In total, twice as many lesions were detected with 64 Cu-DOTATATE than with 111 In-DTPA-OC. Moreover, in 40 of 112 cases (36%) lesions were detected by 64 Cu-DOTATATE in organs not identified as disease-involved by 111 In-DTPA-OC. Conclusion: With these results, we demonstrate that 64 Cu-DOTATATE is far superior to 111 In-DTPA-OC in diagnostic performance in NET patients. Therefore, we do not hesitate to recommend implementation of 64 Cu-DOTATATE as a replacement for 111 In-DTPA-OC.

show abstract

Section: Discussionmentioning

confidence: 84%

⁶⁴Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with ¹¹¹In-DTPA-Octreotide in 112 Patients

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Somatostatin receptor PET/CT is increasingly used in patients with known or suspected neuroendocrine tumours demonstrating high diagnostic accuracy and is superior compared to 111 In-pentetreotide scintigraphy in this setting [6,7]. Recent articles in the literature assessed the diagnostic accuracy of somatostatin receptor PET/CT using different somatostatin analogues labelled with 68 Ga ( 68 Ga-DOTATATE, 68 Ga-DOTANOC and 68 Ga-DOTATOC) in patients with extraadrenal PGL [8][9][10][11][12][13][14][15][16][17], based on the increased expression of somatostatin receptors in PGL neoplastic cells [18].…”

mentioning

confidence: 99%

Could 68Ga-somatostatin analogues replace other PET tracers in evaluating extra-adrenal paragangliomas?

Treglia

Giovanella

2013

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

“…Somatostatin receptor PET/CT using somatostatin analogues labelled with gallium-68 is a valuable diagnostic tool for patients with neuroendocrine tumours (NETs) [21,22]. The experience with somatostatin receptor PET/CT in recurrent MTC is limited compared to FDG and F-DOPA [9].…”

Section: B)mentioning

confidence: 99%

The 2015 Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma: the “evidence-based” refusal to endorse them by EANM due to the “not evidence-based” marginalization of the role of Nuclear Medicine

Treglia

Aktolun²,

Chiti

et al. 2016

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

In 2007, the American Thyroid Association (ATA) assembled a group of expert clinicians and basic scientists to evaluate published papers and to develop evidence-based guidelines for the diagnosis and management of patients with medullary thyroid carcinoma (MTC). The first ATA guidelines on the management of patients with MTC were published in 2009 [1]. In 2015, ATA released the first revised version of these guidelines [2], in order to assist clinicians of all specialties in the management of these patients.The ATA Board of Directors selected the Task Force members for elaborating these revised guidelines based on published scientific data in the management of MTC, and included international scientists from the fields of endocrinology, ethics, genetics, medical oncology, molecular biology, nuclear medicine, pathology, paediatrics, radiation oncology, and surgery [2]. Task Force members reviewed relevant articles on MTC by searching MEDLINE/PubMed from January 1980 to April 2014 using specific MTC-related search terms. Task Force members also provided additional relevant articles, book chapters, and other materials. Recommendations were graded using criteria adapted from the United States Preventive Services Task Force Agency for Healthcare Research and Quality as were used in the previous MTC guidelines [1,2]. After revisions and critical reviews of a series of drafts, the Task Force developed a final document, and the ATA Board of Directors approved the revised set of guidelines [2].Compared to the earlier version [1], the 2015 revised ATA guidelines on the management of patients with MTC (now consisting of 67 recommendations and related explanatory * Giorgio Treglia giorgiomednuc@libero.it on behalf of the EANM and the EANM Thyroid Committee

show abstract

Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis

Abstract: SMSR PET has good diagnostic performance for evaluation of NET in the thorax and abdomen, better than SRS which has been the previous standard method. This meta-analysis gives further support for switching to SMSR PET.

Cited by 182 publications

References 53 publications

⁶⁴Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with ¹¹¹In-DTPA-Octreotide in 112 Patients

⁶⁴Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with ¹¹¹In-DTPA-Octreotide in 112 Patients

Could 68Ga-somatostatin analogues replace other PET tracers in evaluating extra-adrenal paragangliomas?

The 2015 Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma: the “evidence-based” refusal to endorse them by EANM due to the “not evidence-based” marginalization of the role of Nuclear Medicine

Contact Info

Product

Resources

About

Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis

Abstract: SMSR PET has good diagnostic performance for evaluation of NET in the thorax and abdomen, better than SRS which has been the previous standard method. This meta-analysis gives further support for switching to SMSR PET.

Cited by 182 publications

References 53 publications

64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients

64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients

Could 68Ga-somatostatin analogues replace other PET tracers in evaluating extra-adrenal paragangliomas?

The 2015 Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma: the “evidence-based” refusal to endorse them by EANM due to the “not evidence-based” marginalization of the role of Nuclear Medicine

Contact Info

Product

Resources

About

⁶⁴Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with ¹¹¹In-DTPA-Octreotide in 112 Patients

⁶⁴Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with ¹¹¹In-DTPA-Octreotide in 112 Patients